ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. T… Read more
ARS Pharmaceuticals, Inc (SPRY) - Net Assets
Latest net assets as of September 2025: $147.66 Million USD
Based on the latest financial reports, ARS Pharmaceuticals, Inc (SPRY) has net assets worth $147.66 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($372.80 Million) and total liabilities ($225.15 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $147.66 Million |
| % of Total Assets | 39.61% |
| Annual Growth Rate | 55.44% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 61.65 |
ARS Pharmaceuticals, Inc - Net Assets Trend (2018–2024)
This chart illustrates how ARS Pharmaceuticals, Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ARS Pharmaceuticals, Inc (2018–2024)
The table below shows the annual net assets of ARS Pharmaceuticals, Inc from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $256.80 Million | +11.28% |
| 2023-12-31 | $230.76 Million | -15.44% |
| 2022-12-31 | $272.89 Million | +972.70% |
| 2021-12-31 | $-31.27 Million | -122.52% |
| 2020-12-31 | $-14.05 Million | -150.79% |
| 2019-12-31 | $-5.60 Million | -130.79% |
| 2018-12-31 | $18.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ARS Pharmaceuticals, Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8348500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.00K | 0.00% |
| Other Comprehensive Income | $220.00K | 0.09% |
| Other Components | $379.87 Million | 147.93% |
| Total Equity | $256.80 Million | 100.00% |
ARS Pharmaceuticals, Inc Competitors by Market Cap
The table below lists competitors of ARS Pharmaceuticals, Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
United Parks & Resorts Inc
NYSE:PRKS
|
$874.92 Million |
|
ZHEJIANG ASIA-PACIFIC MECHANICAL & ELECTRONIC CO LTD
SHE:002284
|
$875.17 Million |
|
Altarea
LSE:0IRK
|
$875.95 Million |
|
Sumitomo Pharma Co. Ltd
PINK:SMDPY
|
$876.03 Million |
|
Streamax Technology Co Ltd
SHE:002970
|
$874.67 Million |
|
CVR Energy Inc
NYSE:CVI
|
$874.31 Million |
|
PLUXEE NV
PA:PLX
|
$873.75 Million |
|
Kiwi Property Group Limited
PINK:KWIPF
|
$873.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ARS Pharmaceuticals, Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 230,760,000 to 256,798,000, a change of 26,038,000 (11.3%).
- Net income of 7,998,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 171,000.
- Other factors increased equity by 17,869,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $8.00 Million | +3.11% |
| Other Comprehensive Income | $171.00K | +0.07% |
| Other Changes | $17.87 Million | +6.96% |
| Total Change | $- | 11.28% |
Book Value vs Market Value Analysis
This analysis compares ARS Pharmaceuticals, Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.54x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 16.15x to 3.54x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $0.55 | $8.89 | x |
| 2019-12-31 | $-0.17 | $8.89 | x |
| 2020-12-31 | $-0.40 | $8.89 | x |
| 2021-12-31 | $-1.08 | $8.89 | x |
| 2022-12-31 | $6.83 | $8.89 | x |
| 2023-12-31 | $2.42 | $8.89 | x |
| 2024-12-31 | $2.51 | $8.89 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ARS Pharmaceuticals, Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.97%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.37x
- Recent ROE (3.11%) is above the historical average (-18.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -96.60% | 0.00% | 0.00x | 1.51x | $-19.40 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-23.41 Million |
| 2020 | 0.00% | -5.97% | 0.68x | 0.00x | $340.20K |
| 2021 | 0.00% | -367.65% | 0.09x | 0.00x | $-17.12 Million |
| 2022 | -12.71% | -2635.41% | 0.00x | 1.03x | $-61.97 Million |
| 2023 | -23.56% | -181216.67% | 0.00x | 1.01x | $-77.44 Million |
| 2024 | 3.11% | 8.97% | 0.25x | 1.37x | $-17.68 Million |
Industry Comparison
This section compares ARS Pharmaceuticals, Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ARS Pharmaceuticals, Inc (SPRY) | $147.66 Million | -96.60% | 1.52x | $874.81 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |